

# HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy

Anna C. Hearps<sup>a,b</sup>, Anna Maisa<sup>a</sup>, Wan-Jung Cheng<sup>a</sup>,  
Thomas A. Angelovich<sup>a,c</sup>, Gregor F. Lichtfuss<sup>a,b</sup>, Clovis S. Palmer<sup>a,d</sup>,  
Alan L. Landay<sup>e</sup>, Anthony Jaworowski<sup>a,b,f,\*</sup> and  
Suzanne M. Crowe<sup>a,b,g,\*</sup>

**Objectives:** To compare the impact of HIV infection and healthy ageing on monocyte phenotype and function and determine whether age-related changes induced by HIV are reversed in antiretroviral treated individuals.

**Design:** A cross sectional study of monocyte ageing markers in viremic and virologically suppressed HIV-positive males aged 45 years or less and age-matched and elderly ( $\geq 65$  years) HIV-uninfected individuals.

**Methods:** Age-related changes to monocyte phenotype and function were measured in whole blood assays *ex vivo* on both CD14<sup>++</sup>CD16<sup>-</sup> (CD14<sup>+</sup>) and CD14<sup>variable</sup>CD16<sup>+</sup> (CD16<sup>+</sup>) subsets. Plasma markers relevant to innate immune activation were measured by ELISA.

**Results:** Monocytes from young viremic HIV-positive males resemble those from elderly controls, and show increased expression of CD11b ( $P < 0.0001$  on CD14<sup>+</sup> and CD16<sup>+</sup> subsets) and decreased expression of CD62L and CD115 ( $P = 0.04$  and  $0.001$ , respectively, on CD14<sup>+</sup> monocytes) when compared with young uninfected controls. These changes were also present in young virologically suppressed HIV-positive males. Innate immune activation markers neopterin, soluble CD163 and CXCL10 were elevated in both young viremic ( $P < 0.0001$  for all) and virologically suppressed ( $P = 0.0005$ ,  $0.003$  and  $0.002$ , respectively) HIV-positive males with levels in suppressed individuals resembling those observed in elderly controls. Like the elderly, CD14<sup>+</sup> monocytes from young HIV-positive males exhibited impaired phagocytic function ( $P = 0.007$ ) and telomere shortening ( $P = 0.03$ ) as compared with young uninfected controls.

**Conclusion:** HIV infection induces changes to monocyte phenotype and function in young HIV-positive males that mimic those observed in elderly uninfected individuals, suggesting HIV may accelerate age-related changes to monocytes. Importantly, these defects persist in virologically suppressed HIV-positive individuals.

© 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins

*AIDS* 2012, **26**:843–853

**Keywords:** combination antiretroviral therapy, HIV, immune activation, innate immunity, monocyte, telomere length

<sup>a</sup>Centre for Virology, Burnet Institute, <sup>b</sup>Department of Medicine, Monash University, <sup>c</sup>School of Applied Sciences, RMIT University, Melbourne, Victoria, <sup>d</sup>School of Medical Sciences, University of New South Wales, Sydney, New South Wales, Australia, <sup>e</sup>Rush University Medical Center, Chicago, Illinois, USA, <sup>f</sup>Department of Immunology, Monash University, and <sup>g</sup>Infectious Diseases Unit, Alfred Hospital, Melbourne, Victoria, Australia.

Correspondence to Dr Anna C. Hearps, Centre for Virology, Burnet Institute, GPO Box 2284, Melbourne, VIC 3001, Australia. Tel: +61 03 9282 2150; fax: +61 03 9282 2142; e-mail: annah@burnet.edu.au

\* Anthony Jaworowski and Suzanne M. Crowe contributed equally to the writing of this article.

Received: 15 November 2011; revised: 26 January 2012; accepted: 30 January 2012.

DOI:10.1097/QAD.0b013e328351f756

## Introduction

The increased life expectancy of HIV-positive individuals due to combination antiretroviral therapy (cART) has revealed an increased incidence of non-AIDS comorbidities more commonly seen in the elderly, such as cardiovascular disease [1], frailty [2], bone and renal disease [3] and neurocognitive decline [4]. Although the pathogenesis of age-related diseases is complex and multifactorial, these conditions are associated with an ageing and dysregulated immune system. The increased prevalence of these diseases and their premature onset in HIV-positive individuals suggest HIV may induce premature immune ageing.

Immune ageing results from a lifetime of pathogen stimulation and is characterized by an increase in senescent CD8<sup>+</sup>CD28<sup>-</sup> T cells [5] and a state of chronic inflammation that drives age-related immune dysfunction and disease [6,7]. Elevated plasma levels of inflammatory markers [e.g. interleukin (IL)-6] predict age-related diseases including cardiovascular disease, frailty and mortality [8–12]. HIV-positive individuals share many immunological characteristics with the elderly including chronic inflammation (reviewed in [13]), an increased proportion of senescent T cells with shortened telomeres [14,15] and increased risk of age-related disease. Similar factors may drive chronic immune activation and inflammation in HIV-positive individuals and the elderly and include the following: first, increased pathogen burden due to impaired immunity; second, chronic viral replication by viruses such as cytomegalovirus, a well recognized driver of ageing [16,17] and HIV; and, third, microbial translocation of bacterial products across damaged mucosal surfaces, for example the gut [18,19].

In untreated HIV-positive individuals, the level of T-cell activation is the strongest predictor of mortality [20], but the predictive value of T-cell activation markers in the post-cART era is unclear. T-cell activation in HIV-positive individuals is primarily driven by viral replication, which is significantly suppressed by cART, although residual activation persists [21]. In contrast, cART does not normalize levels of innate immune stimulants such as lipopolysaccharide (LPS) [22], and innate immune activation persists in cART-treated individuals [22,23]. A recent study of HIV-positive individuals (the majority being virologically suppressed) found levels of the monocyte/macrophage activation marker, soluble CD14 (sCD14), independently predict all-cause mortality [24]. In cART-treated individuals, sCD14 levels correlate with inflammatory markers such as IL-6, high-sensitivity C-reactive protein and D-dimer [24] that predict cardiovascular disease, whereas elevated sCD163 levels are associated with increased formation of noncalcified plaques [25]. Thus, the persistence of innate immune stimuli in virologically suppressed individuals may contribute to HIV-related morbidity and mortality in the post-cART era.

LPS levels remain elevated in cART-treated individuals with a decay half-life of up to 13 years [22], yet the impact of this on the phenotype and function of innate immune cells remains unknown. Monocytes/macrophages are the major responders to LPS due to their high expression of the LPS receptor Toll-like receptor (TLR)4 and its related signaling molecule CD14 [26] and are primary producers of pro-inflammatory cytokines such as tumor necrosis factor (TNF) and IL-6. Monocytes have specific roles in the pathogenesis of age-related diseases, for example in foam cell formation during the development of atherosclerotic plaques [27] and in HIV-associated dementia [28]. Given that the stimuli to which monocytes respond remain elevated in cART-treated individuals, monocyte activation may be an independent predictor of age-related comorbidities in virologically suppressed HIV-positive individuals.

We sought to determine whether HIV infection prematurely induces age-related changes to monocytes by directly comparing the phenotype and function of monocytes from young HIV-positive individuals to both age-matched and elderly HIV-uninfected controls. Our findings confirm that HIV infection is associated with a premature induction of age-related changes to monocytes and support the hypothesis that HIV may accelerate immune ageing and, thus, hasten the development of age-related diseases.

## Methods

### Participant recruitment and blood separation

Viremic (median RNA viral load 41 600 copies/ml, range 80–>100 000; median CD4 T cells 434 cells/ $\mu$ l, range 11–1092) and virologically suppressed (RNA viral load <50 copies/ml; median CD4 T cells 695 cells/ $\mu$ l, range 209–1199; median time of viral suppression 2.8 years, range 0.7–7.6) HIV-positive individuals 45 years or less were recruited from the Infectious Diseases Unit at The Alfred Hospital, Melbourne, Victoria, Australia. Young ( $\leq$ 45 years) and aged ( $\geq$ 65 years) HIV-negative controls were recruited from the community. Ethical approval was obtained from The Alfred Hospital Research and Ethics Committee. Male participants were exclusively recruited because HIV-positive individuals in Australia are predominantly male. Exclusion criteria included current use of anti-inflammatory medication and recent ( $\leq$ 3 weeks) vaccination or self-reported illness/injury. Plasma separation and peripheral blood mononuclear cell (PBMC) preparation (via Ficoll gradient centrifugation) was performed within 2 h of blood collection.

### Monocyte phenotyping

Blood collected into EDTA anticoagulant was mixed with a 20:1 FACS (fluorescence-activated cell sorting)

lysing solution (BD Biosciences, Franklin Lakes, New Jersey, USA) to lyse erythrocytes (shown not to significantly alter expression of relevant surface markers), incubated on ice for 10 min and then washed twice with FACS wash [1% heat-inactivated cosmic calf serum, 2 mmol/l EDTA in calcium-free and magnesium-free PBS (Invitrogen, Carlsbad, California, USA)]. Cells were stained on ice for 30 min using pretitrated volumes of the following antibodies: CD14-APC, CD16-PE.Cy7, CD38-PE, HLA(human leukocyte antigen)-DR-FITC, CD11b-PE, CD62L-FITC (BD Biosciences), TLR4-FITC (R&D Systems, Minneapolis, Minnesota, USA) and CD115-PE (eBiosciences, San Diego, California, USA) or appropriate isotype control antibodies. Cells were washed once in FACS wash and fixed in 1% formaldehyde. Samples were analyzed on a dual-laser BD FACSCalibur flow cytometer.

### Assessment of monocyte phagocytosis

Phagocytic capacity of monocytes was determined using heat-killed *Escherichia coli* labeled with the pH-dependent dye pHRODO (Invitrogen) as per manufacturer's instructions.  $2 \times 10^8$  labeled *E. coli* was added to 100  $\mu$ l of whole blood collected into heparin anticoagulant and incubated either at 37°C or on ice for 10 min. Red blood cells were lysed and monocytes labeled with CD14-APC and analyzed as described above.

### Analysis of telomere length

Telomere length in monocyte subsets was determined via immunophenotyping and fluorescence *in situ* hybridization (FISH)-Flow using modification of a previously described protocol [29]. PBMCs were labeled with anti-CD14-Qdot 800, anti-CD3-AlexaFluor 405 (both from Invitrogen) and anti-CD16-AlexaFluor 647 (Biolegend, San Diego, California, USA) and cross-linked with 4 mmol/l bis(sulfosuccinimidyl)suberate. Telomeres were stained with the FITC FISH-Flow telomere labelling kit (Dako, Glostrup, Denmark) as per manufacturer's instructions using a 7-Aminoactinomycin D DNA stain (0.1  $\mu$ g/ml). Samples were analyzed on a LSR II flow cytometer (BD Biosciences) and relative telomere length of monocyte subsets determined as a percentage of the internal control cell line 1301 [30].

### Measurement of soluble markers of innate immune activation

Plasma protein and endotoxin measurements were performed using frozen EDTA plasma (subjected to only one freeze-thaw), which was clarified via centrifugation at 10 000g for 10 min prior to analysis. LPS levels were determined in plasma diluted 1:10 and heat inactivated (80°C for 10 min) using the chromogenic Limulus Amebocyte Lysate kit (Lonza, Basel, Switzerland, catalogue number 50-647U). Commercial ELISA kits were used to determine levels of sCD163 (IQ products, Groningen, The Netherlands, catalogue number

IQP-383), neopterin (Screening EIA, Brahms, Berlin, Germany, catalogue number 99R.096), sCD14, CXCL10 and macrophage-colony stimulating factor (M-CSF; catalogue number DC140, DIP100 and DMC00B, respectively, all from Quantikine, R&D Systems), as per manufacturer's instructions.

### Data and statistical analysis

Analysis of flow cytometric data was performed using GateLogic software (Invai, Melbourne, Australia). Graphing and statistical analysis was performed using Prism version 5.0 (GraphPad Software, La Jolla, California, USA). Mann-Whitney *U*-test was used to detect significant differences between sample groups (for nonparametric data) and significant correlations detected via Spearman's correlation analysis.


## Results

### Monocyte subsets

Peripheral blood monocytes were gated as CD14<sup>variable</sup>CD16<sup>+</sup> (referred to as CD16<sup>+</sup>) and CD14<sup>++</sup>CD16<sup>-</sup> (referred to as CD14<sup>+</sup>) subsets (Fig. 1a). There was a significant increase in the proportion of CD16<sup>+</sup> monocytes in elderly individuals ( $P=0.003$ , Fig. 1b). An expansion of this population was also observed in young viremic ( $P=0.003$ ) but not in virologically suppressed ( $P=0.47$ ) HIV-positive males (Fig. 1b). In addition to the expansion of total CD16<sup>+</sup> monocytes, the CD14<sup>+</sup> monocyte subset (typically negative for CD16) in both viremic and virologically suppressed HIV-positive males exhibited an increased expression of CD16 (exemplified in Fig. 1c;  $P=0.001$  for both, Fig. 1d).

### Changes to monocyte phenotype induced by age and HIV

A panel of monocyte phenotypic markers that reflect immune activation and monocyte function was initially screened using blood from healthy young and elderly individuals to identify biomarkers of monocyte ageing (see supplementary data, <http://links.lww.com/QAD/A207>). We used ex-vivo whole blood analyses in this study, as we and others have shown that PBMC preparation can alter surface expression of certain monocyte receptors [31,32]. Monocytes from elderly individuals had significantly altered expression of the adhesion molecules CD62L (CD14<sup>+</sup> monocytes,  $P=0.02$ ) and CD11b (CD16<sup>+</sup> and CD14<sup>+</sup> monocytes,  $P=0.002$  and 0.0005, respectively), the LPS receptor TLR4 (CD16<sup>+</sup> monocytes,  $P=0.007$ ) and the M-CSF receptor CD115 (CD14<sup>+</sup> monocytes,  $P=0.03$ ) as compared with young men. Expression of HLA-DR and CD38 was high on all monocytes, but was not significantly altered by age in our cohort (data not shown), thus was not further analyzed.




**Fig. 1. Proportions of monocyte subsets and CD16 expression levels.** (a) Peripheral blood monocytes were gated initially via forward and side scatter then separated into subsets based on expression of CD14 and CD16. Monocyte subsets were analyzed as either CD14<sup>variable</sup>CD16<sup>+</sup> (CD16<sup>+</sup>) or CD14<sup>+</sup>CD16<sup>-</sup> (CD14<sup>+</sup>). (b) The proportion of monocytes expressing CD16 calculated as (CD16<sup>+</sup> monocytes)/(CD16<sup>+</sup> + CD14<sup>+</sup> monocytes) in young healthy controls (closed circles), elderly healthy controls (open circles), young viremic HIV-positive (closed triangles) and young combination antiretroviral therapy (cART)-treated virologically suppressed HIV-positive males (open triangles). Median ages and ranges for each group are shown below the relevant group label on the x-axis. Median values and interquartile ranges are shown. The *P* values were calculated by Mann–Whitney analysis. (c) Expression of CD14 and CD16 on monocytes from a representative HIV-positive male. (d) Expression of CD16 (MFI, geometric mean fluorescence intensity) on the CD14<sup>+</sup> monocyte population in young and elderly healthy controls and young HIV-positive males (viremic and virologically suppressed) as detailed in (b).

Age-related changes to monocyte phenotype were then analyzed in young HIV-positive individuals. The same pattern of phenotypic change was found in young viremic HIV-positive males as in the elderly, but the magnitude of these changes was greater. Compared with young controls, monocytes from viremic HIV-positive individuals had significantly decreased expression of CD62L (CD14<sup>+</sup> monocytes,  $P=0.04$ , Fig. 2a), decreased expression of CD115 (CD14<sup>+</sup> monocytes,  $P=0.001$ , Fig. 2b) and increased expression of CD11b ( $P<0.0001$  for both monocyte subsets, Fig. 2c and d). Surface expression of CD11b on monocytes from young viremic HIV-positive individuals was significantly higher than that seen in the elderly ( $P=0.003$  and  $0.0003$  for CD14<sup>+</sup> and CD16<sup>+</sup> monocytes, respectively), whereas expression of CD62L and CD115 was not significantly different between young HIV-positive individuals and the elderly. Monocytes from young

HIV-positive individuals did not show significantly altered expression of TLR4 (data not shown).

Similar age-related changes in monocyte phenotype were also observed in young virologically suppressed HIV-positive individuals (Fig. 2a–d). Their monocytes showed significantly increased expression of CD11b ( $P=0.002$  for both CD14<sup>+</sup> and CD16<sup>+</sup> monocytes) and decreased expression of CD62L (CD14<sup>+</sup> monocytes,  $P=0.03$ ) and CD115 expression (CD14<sup>+</sup> monocytes,  $P=0.03$ ) as compared with age-matched controls; expression levels were not significantly different to the elderly. Virologically suppressed HIV-positive individuals showed reduced CD11b expression as compared with viremic patients; however, changes in expression of CD62L or CD115 with treatment were not observed. These data indicate that monocytes from young HIV-positive individuals exhibit a phenotype that mimics changes seen in elderly



**Fig. 2. Expression of CD62L, CD11b and CD115 on monocytes.** Phenotyping of surface receptors was performed on peripheral monocytes in whole blood from young healthy controls (closed circles), elderly healthy controls (open circles), young viremic HIV-positive (closed triangles) and young combination antiretroviral therapy (cART)-treated virologically suppressed HIV-positive males (open triangles). Median ages and ranges for each group are shown below the relevant group label on the x-axis. Expression of (a) CD62L and (b) CD115 on CD14<sup>+</sup> monocytes and CD11b on (c) CD14<sup>+</sup> and (d) CD16<sup>+</sup> monocytes measured as ΔMFI (geometric mean fluorescence intensity of stain minus fluorescence of isotype control) is shown. Median values and interquartile ranges are shown. The *P* values were calculated by Mann–Whitney analysis and are shown for values less than 0.05.

healthy HIV-negative individuals and that these defects persist in cART-treated individuals.


### Soluble mediators and markers of innate immune activation

To compare the impact of ageing and HIV on innate immune activation, we measured plasma levels of candidate innate immune activation markers. Neopterin ( $P=0.0001$ ), CXCL10 ( $P=0.004$ ) and sCD163 ( $P=0.004$ ) were significantly elevated in the elderly compared with young individuals (Fig. 3a–c), whereas levels of sCD14 and M-CSF were not significantly altered (data not shown). In young viremic HIV-positive individuals, plasma levels of neopterin, CXCL10 and sCD163 were significantly elevated when compared with both young ( $P<0.0001$  for all) and elderly ( $P<0.0001$  for neopterin and CXCL10 and 0.005 for sCD163) controls (Fig. 3a–c). Plasma levels of these markers were significantly reduced in virologically suppressed as compared with viremic HIV-positive individuals, but remained elevated above those of age-matched HIV-uninfected controls ( $P=0.0005$ , 0.002 and 0.003 for neopterin, CXCL10 and sCD163, respectively) and were not significantly different to elderly controls. We also measured plasma levels of the innate immune stimulant LPS and found significantly elevated levels in elderly controls ( $P=0.006$ ), viremic ( $P=0.005$ ) and virologically suppressed ( $P=0.02$ ) HIV-positive

individuals as compared with young controls (Fig. 3d). These findings support the use of these markers as biomarkers of innate immune ageing and show that they are elevated in young HIV-positive individuals irrespective of viral load.

LPS binding to TLR4 receptors on monocytes leads to production of pro-inflammatory cytokines such as TNF; thus, we hypothesized that elevated LPS levels may be associated with increased production of TNF by monocytes. Basal intracellular levels of TNF in both CD14<sup>+</sup> and CD16<sup>+</sup> whole blood monocytes from elderly and HIV-positive individuals were significantly higher than young controls (see supplementary data, <http://links.lww.com/QAD/A207>), suggesting increased plasma LPS is associated with increased basal production of pro-inflammatory cytokines by monocytes.

We performed regression analyses between soluble innate immune activation markers and phenotypic markers of monocyte ageing and found a significant correlation between CXCL10 and all identified phenotypic markers (Table 1). Plasma levels of neopterin were significantly associated with all phenotypic markers except the proportion of CD16<sup>+</sup> monocytes; sCD163 levels correlated with expression of CD11b on CD16<sup>+</sup> monocytes; and plasma LPS levels correlated with the proportion of CD16<sup>+</sup> monocytes.



**Fig. 3. Plasma levels of innate immune activation markers.** Plasma levels of (a) neopterin, (b) CXCL10 and (c) soluble CD163 (sCD163) were determined via ELISA, and (d) lipopolysaccharide (LPS) determined by the Limulus Amoebocyte Lysate assay. Values are shown for young healthy controls (closed circles), elderly healthy controls (open circles), young viremic HIV-positive (closed triangles) and young combination antiretroviral therapy (cART)-treated HIV-positive individuals (open triangles). Median ages and ranges for each group are shown below the relevant group label on the x-axis. Median values and interquartile ranges are shown. The *P* values were calculated via Mann–Whitney analysis and are shown for values less than 0.05.

### Monocyte function

To determine whether monocyte function is altered by ageing or HIV infection, we examined the phagocytic ability of peripheral blood monocytes (Fig. 4a). The percentage of phagocytic monocytes was significantly reduced in elderly ( $P=0.04$ ) and young viremic HIV-positive males ( $P=0.007$ ) as compared with young controls with the proportion of phagocytic cells not differing significantly between elderly controls and HIV-positive individuals ( $P=0.6$ ).


### Monocyte telomere length

HIV infection is associated with accelerated telomere-shortening in  $CD8^+$  T cells [33,34] and in B cells [35]. The impact of HIV infection on telomere length in innate immune cells is unknown. Using a multicolor FISH-Flow protocol, we demonstrated that both  $CD14^+$  and  $CD16^+$  monocytes from young HIV-positive individuals contain significantly shorter telomeres than young controls ( $P=0.03$  and  $0.02$  for  $CD14^+$  and  $CD16^+$ , respectively, Fig. 4b and c), which were not significantly different to

**Table 1. Correlation of soluble and monocyte phenotypic markers of ageing.**

	Neopterin		CXCL10		Soluble CD163		LPS	
	<i>rho</i>	<i>P</i> value	<i>rho</i>	<i>P</i> value	<i>rho</i>	<i>P</i> value	<i>rho</i>	<i>P</i> value
% $CD16^+$ monocytes	0.09	NS (0.53)	0.405	0.009	0.098	NS (0.55)	0.317	0.032
CD11b on $CD14^+$ monocytes	0.300	0.03	0.675	<0.0001	0.151	NS (0.36)	0.177	NS (0.24)
CD11b on $CD16^+$ monocytes	0.418	0.002	0.653	<0.0001	0.318	0.05	0.024	NS (0.88)
CD62L on $CD14^+$ monocytes	-0.36	0.01	-0.584	<0.0001	-0.084	NS (0.63)	-0.177	NS (0.26)
CD115 on $CD14^+$ monocytes	-0.291	0.03	-0.37	0.02	0.011	NS (0.95)	-0.115	NS (0.45)

Plasma levels of soluble markers of innate immune activation were correlated with age-related changes to monocyte phenotypic markers for all samples tested using Spearman's rank correlation coefficient (*rho*). LPS, lipopolysaccharide.



**Fig. 4. Monocyte function and telomere length.** (a) The phagocytic function of monocytes was determined by whole blood flow cytometry using pHRODO-labeled *Escherichia coli* phagocytic target. Values shown indicate percentage CD14<sup>+</sup> monocytes that had phagocytosed the target for young healthy controls (closed circles), elderly healthy controls (open circles) and young viremic HIV-positive (closed triangles) individuals. Median values and interquartile ranges are shown. The  $P$  values were calculated via Mann–Whitney analysis. Telomere length of CD14<sup>+</sup> (b) and CD16<sup>+</sup> (c) monocyte subsets and CD3<sup>+</sup> T cells (d) was determined via FISH-Flow and immunophenotyping. Values represent relative telomere length (RTL) expressed as a percentage of the internal control cell line 1301 for young healthy controls (closed circles; median age 28 years, range 20–32), elderly healthy controls (open circles; median age 72 years, range 70–82), young viremic HIV-positive (closed triangles; median age 39 years, range 27–45). Median values and interquartile ranges are shown. The  $P$  values were calculated via Mann–Whitney analysis.

elderly controls ( $P = 0.3$  and  $0.4$  for CD14<sup>+</sup> and CD16<sup>+</sup> monocytes, respectively). In contrast, although age was associated with a significant decrease in telomere length in CD3<sup>+</sup> T cells, telomere length in T cells from young HIV-positive individuals was not different to young controls ( $P = 0.5$ , Fig. 4d). These data indicate that HIV infection is associated with telomere-shortening in monocytes.

## Discussion

Increasing evidence suggests HIV infection induces premature ageing of the adaptive immune system. Ageing also hastens the development of age-related diseases with inflammatory causes, yet the impact of HIV on age-related changes to innate cells critical for regulating inflammation (e.g. monocytes) is unknown. Here we directly compared monocytes from young HIV-positive males with young and elderly healthy controls and found

that young HIV-positive individuals show changes to monocyte phenotype, function and telomere length that closely resemble those observed in elderly controls aged approximately 30 years older. Furthermore, our data suggest these immune defects are not fully restored by cART.

We found that similar to elderly controls, the proportion of CD16<sup>+</sup> monocytes (considered inflammatory due to their high production of TNF [36]) was increased in young viremic HIV-positive individuals. An increase in this subset has been reported in other inflammatory conditions [37–39] in association with ageing [40] and in patients with HIV-related dementia [28]. Our finding of increased CD16<sup>+</sup> monocytes in viremic but not cART-treated individuals is consistent with data from ourselves and others [41,42]. Distinct from the increased proportion of CD16<sup>+</sup> monocytes, we also observed an increase in CD16 expression on the CD14<sup>+</sup> monocyte population seen specifically in HIV-positive individuals. Although the functional implications of this novel finding

remain to be defined, CD14<sup>+</sup> monocytes are thought to be precursors for the mature CD16<sup>+</sup> subsets and an increase in double positive (CD14<sup>+</sup>CD16<sup>+</sup>) monocytes is a preliminary step in M-CSF-induced expansion of CD16<sup>+</sup> monocytes *in vivo* [43]. This is consistent with our finding of significantly increased plasma M-CSF levels in viremic (median 177 pg/ml,  $P=0.0002$ ) and virologically suppressed (median 141,  $P=0.04$ ) HIV-positive individuals, but not elderly individuals as compared with young controls (median 115 pg/ml, data not shown), suggesting increased CD16 expression on CD14<sup>+</sup> monocytes may reflect an increased rate of monocyte maturation induced by cytokines such as M-CSF in HIV-positive individuals. The fact that increased expression of CD16 on CD14<sup>+</sup> monocytes persists in virologically suppressed individuals while the proportion of CD16<sup>+</sup> monocytes is normalized suggests that different factors may drive these two processes, but the net effect of these changes on the inflammatory potential of monocyte subsets remains to be determined.

Monocytes from young HIV-positive individuals exhibited other age-related changes including increased surface expression of CD11b (a component of the  $\beta 2$ -integrin macrophage-1 antigen) and decreased expression of the adhesion molecule CD62L. CD11b is a marker of monocyte activation; macrophage-1 antigen is involved in migration of monocytes into atherosclerotic plaques [44] and increased CD11b expression has been associated with atherosclerosis in a mouse model [45]. Exposure of monocytes from healthy donors to either TNF $\alpha$ , LPS or immune complexes reduces CD62L expression and increases CD11b expression [46,47], suggesting that changes in monocyte phenotype observed here may be in part due to a pro-inflammatory state present in both the elderly and HIV-positive individuals. CD62L and CD11b are required for endothelial attachment and migration of monocytes, and HIV infection of monocytic cell lines increases CD11b expression and increases endothelial attachment [48]. Reduced expression of the M-CSF receptor CD115 was also found on monocytes from the elderly and viremic HIV-positive individuals, which in HIV-positive individuals may be a consequence of elevated M-CSF levels leading to increased CD115 internalization and degradation [49]. Alternatively, LPS has been shown to reduce M-CSF receptor expression on mouse macrophages [50]. The functional implications of reduced CD115 expression are not known, but may alter the ratio of M-CSF-stimulated 'anti-inflammatory' M2 monocytes and granulocyte-macrophage (GM)-CSF-stimulated 'inflammatory' M1 macrophages [51].

We have confirmed and extended previous findings of elevated plasma levels of neopterin, sCD163 and CXCL10 in HIV-positive individuals [23,52,53] by identifying that levels of these innate immune activation markers in virologically suppressed HIV-positive individuals were similar to those in elderly controls and are

linked with age-related changes to monocyte phenotype. Elevation of these markers in virologically suppressed HIV-positive individuals suggests factors other than HIV viremia may drive persistent innate immune activation, although the contribution of residual viral replication cannot be excluded. Neopterin and CXCL10 are implicated in frailty, atherogenesis and neurological defects in elderly individuals [54–56], whereas in HIV-positive individuals elevated neopterin is associated with impaired cognitive function and AIDS-related dementia [57] and elevated sCD163 with noncalcified coronary plaques [25]. The neurotoxic chemokine CXCL10 is also upregulated in patients with HIV-associated neurocognitive disorders [58,59] and was the only plasma marker that correlated with all the observed age-related changes to monocyte phenotype, supporting its use as a robust biomarker of monocyte ageing. CXCL10 is produced by monocytes, endothelial cells and fibroblasts in response to interferon (IFN) $\gamma$  [60] and our finding of elevated CXCL10 in elderly and HIV-positive individuals suggests elevated IFN $\gamma$  levels in these individuals. LPS directly stimulates monocytes and is elevated in both the elderly and HIV-positive individuals irrespective of viral load. Our finding of increased basal levels of the pro-inflammatory cytokine TNF in monocytes from both elderly and HIV-positive individuals suggests that persistent innate immune activation by factors such as LPS may contribute to chronic inflammation in both groups. The significant association of innate immune activation markers with age-related HIV comorbidities warrants further work to elucidate the drivers of persistent innate immune activation in virologically suppressed individuals.

Our data showing telomere-shortening in monocytes from both young HIV-positive individuals and the elderly was surprising. Human monocytes do not undergo significant cell division, thus shortened telomeres are unlikely to reflect enhanced peripheral cell division. These data more likely reflect telomere-shortening in bone marrow precursor cells, suggesting HIV infection drives increased precursor cell turnover. This hypothesis is consistent with the findings of Burdo *et al.* [61] that show increased monocyte turnover in simian immunodeficiency virus-infected macaques that correlated with increased levels of sCD163 and severity of encephalitis. Increased monocyte turnover during HIV infection may be due to persistent immune activation (e.g. secondary to microbial translocation), causing increased monocyte mobilization from the bone marrow. Reduced activity of the telomere repair enzyme telomerase in CD34<sup>+</sup> hematopoietic progenitor cells from HIV-positive individuals [62] may also contribute. Despite the small sample size, telomere length of CD14<sup>+</sup> monocytes correlated with plasma levels of CXCL10 in our study ( $P=0.03$ , Spearman's  $\rho$   $-0.475$ , data not shown), supporting a link between monocyte activation and telomere-shortening. The functional implications of shortened



telomeres in monocytes/macrophages are not known, but telomere-shortening of leukocytes is associated with age-related diseases including cancer and cardiovascular disease [63]. HIV infection is associated with telomere-shortening in CD8<sup>+</sup> but not CD4<sup>+</sup> T cells [33,34], which may explain why significant telomere-shortening was not detected in total CD3<sup>+</sup> T cells in this study. Our data showing that HIV infection also induces age-related changes to monocyte phagocytosis is consistent with our previous findings [64,65]. Given the observed similarities in monocyte activation and phenotype, it would be of interest to compare the gene expression profiles of monocytes from young and elderly HIV-uninfected and young HIV-positive individuals, which to date has not been done.

In summary, we have shown that young HIV-positive men exhibit age-related changes to monocyte phenotype and levels of innate immune activation that resemble those observed in elderly HIV-uninfected individuals. Importantly, age-related changes to plasma and phenotypic markers of monocyte activation (e.g. neopterin, CXCL10, sCD163 and CD11b expression) are not normalized by cART, which may have implications for the development of comorbidities involving activated monocytes (e.g. atherosclerosis) in virologically suppressed HIV-positive individuals. Given the strong links between chronic inflammation and age-related comorbidities, our findings have important clinical implications. Future longitudinal studies are required to investigate the impact of time of viral suppression on innate ageing biomarkers and determine whether the rate of ageing is increased by HIV. Elucidating the mechanisms driving age-related changes in the absence of overt viremia is required to prevent comorbidities in this population. This study has identified biomarkers that may be useful for monitoring immune activation and disease risk in HIV-positive individuals and may also represent new targets for interventional strategies.

## Acknowledgements

A.C.H., A.L.L., A.J. and S.M.C. designed the study, whereas A.C.H., A.M., W.-J.C., T.A.A., G.F.L. and C.S.P. produced experimental data. A.C.H. prepared the manuscript with critical review from A.L.L., A.J. and S.M.C. The authors wish to thank the Clinical Research Nurses at The Alfred Hospital's Infectious Diseases Unit for assistance with patient recruitment and Clare Westhorpe for input into study design. The authors gratefully acknowledge the contribution to this work of the Victorian Operational Infrastructure Support Program.

A.M. is supported by the Postdoctoral Programme of the German Academic Exchange Service (DAAD) and S.M.C. is supported by a Principal Research Fellowship

from the Australian National Health and Medical Research Council (NHMRC). The work was funded via NHMRC project grant 543137 to A.J. and S.M.C.

## Conflicts of interest

There are no conflicts of interest.

## References

1. Triant VA, Meigs JB, Grinspoon SK. **Association of C-reactive protein and HIV infection with acute myocardial infarction.** *J Acquir Immune Defic Syndr* 2009; **51**:268–273.
2. Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, *et al.* **HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty.** *J Gerontol A Biol Sci Med Sci* 2007; **62**:1279–1286.
3. Odden MC, Scherzer R, Bacchetti P, Szczech LA, Sidney S, Grunfeld C, *et al.* **Cystatin C level as a marker of kidney function in human immunodeficiency virus infection: the FRAM study.** *Arch Intern Med* 2007; **167**:2213–2219.
4. Ozdener H. **Molecular mechanisms of HIV-1 associated neurodegeneration.** *J Biosci* 2005; **30**:391–405.
5. Effros RB. **Loss of CD28 expression on T lymphocytes: a marker of replicative senescence.** *Dev Comp Immunol* 1997; **21**:471–478.
6. Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, *et al.* **Inflammaging and antiinflammaging: a systemic perspective on aging and longevity emerged from studies in humans.** *Mech Ageing Dev* 2007; **128**:92–105.
7. Ostan R, Bucci L, Capri M, Salvioli S, Scurti M, Pini E, *et al.* **Immunosenescence and immunogenetics of human longevity.** *Neuroimmunomodulation* 2008; **15**:224–240.
8. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, *et al.* **Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly.** *Am J Med* 1999; **106**:506–512.
9. De Martinis M, Franceschi C, Monti D, Ginaldi L. **Inflammation markers predicting frailty and mortality in the elderly.** *Exp Mol Pathol* 2006; **80**:219–227.
10. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, *et al.* **Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review.** *PLoS Med* 2008; **5**:e78.
11. Leng S, Chaves P, Koenig K, Walston J. **Serum interleukin-6 and hemoglobin as physiological correlates in the geriatric syndrome of frailty: a pilot study.** *J Am Geriatr Soc* 2002; **50**:1268–1271.
12. Jenny NS, Tracy RP, Ogg MS, Luong le A, Kuller LH, Arnold AM, *et al.* **In the elderly, interleukin-6 plasma levels and the -174G>C polymorphism are associated with the development of cardiovascular disease.** *Arterioscler Thromb Vasc Biol* 2002; **22**:2066–2071.
13. Appay V, Sauce D. **Immune activation and inflammation in HIV-1 infection: causes and consequences.** *J Pathol* 2008; **214**:231–241.
14. Effros RB, Allsopp R, Chiu CP, Hausner MA, Hirji K, Wang L, *et al.* **Shortened telomeres in the expanded CD28-CD8+ cell subset in HIV disease implicate replicative senescence in HIV pathogenesis.** *AIDS* 1996; **10**:F17–22.
15. Cao W, Jamieson BD, Hultin LE, Hultin PM, Effros RB, Detels R. **Premature aging of T cells is associated with faster HIV-1 disease progression.** *J Acquir Immune Defic Syndr* 2009; **50**:137–147.
16. Derhovanessian E, Larbi A, Pawelec G. **Biomarkers of human immunosenescence: impact of cytomegalovirus infection.** *Curr Opin Immunol* 2009; **21**:440–445.
17. Pawelec G, Derhovanessian E, Larbi A, Strindhall J, Wikby A. **Cytomegalovirus and human immunosenescence.** *Rev Med Virol* 2009; **19**:47–56.
18. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, *et al.* **Microbial translocation is a cause of systemic immune activation in chronic HIV infection.** *Nat Med* 2006; **12**:1365–1371.

19. Deeks SG. **Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy.** *Top HIV Med* 2009; **17**:118–123.
20. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. **Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage.** *J Infect Dis* 1999; **179**:859–870.
21. Jiang W, Lederman MM, Hunt P, Sieg SF, Haley K, Rodriguez B, et al. **Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection.** *J Infect Dis* 2009; **199**:1177–1185.
22. Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, Gouillou M, et al. **Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation.** *J Infect Dis* 2010; **202**:1254–1264.
23. Burdo TH, Lentz MR, Autissier P, Krishnan A, Halpern E, Letendre S, et al. **Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after antiretroviral therapy.** *J Infect Dis* 2011; **204**:154–163.
24. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. **Plasma levels of soluble CD14 independently predict mortality in HIV infection.** *J Infect Dis* 2011; **203**:780–790.
25. Burdo TH, Lo J, Abbara S, Wei J, Deleleys ME, Preffer F, et al. **Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients.** *J Infect Dis* 2011; **204**:1227–1236.
26. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. **Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides.** *J Immunol* 2002; **168**:4531–4537.
27. Gerrity RG, Naito HK. **Ultrastructural identification of monocyte-derived foam cells in fatty streak lesions.** *Artery* 1980; **8**:208–214.
28. Pulliam L, Gascon R, Stubblebine M, McGuire D, McGrath MS. **Unique monocyte subset in patients with AIDS dementia.** *Lancet* 1997; **349**:692–695.
29. Schmid I, Jamieson BD. **Assessment of telomere length, phenotype, and DNA content.** *Curr Protoc Cytom* 2004, Chapter 7:Unit 7 26. pp. 1–13
30. Larsson I, Lundgren E, Nilsson K, Strannegard O. **A human neoplastic hematopoietic cell line producing a fibroblast type of interferon.** *Dev Biol Stand* 1979; **42**:193–197.
31. Tippet E, Cheng WJ, Westhorpe C, Cameron PU, Brew BJ, Lewin SR, et al. **Differential Expression of CD163 on Monocyte Subsets in Healthy and HIV-1 Infected Individuals.** *PLoS One* 2011; **6**:e19968.
32. Lundahl J, Hallden G, Hallgren M, Skold CM, Hed J. **Altered expression of CD11b/CD18 and CD62L on human monocytes after cell preparation procedures.** *J Immunol Methods* 1995; **180**:93–100.
33. Wolthers KC, Bea G, Wisman A, Otto SA, de Roda Husman AM, Schaft N, et al. **T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover.** *Science* 1996; **274**:1543–1547.
34. Palmer LD, Weng N, Levine BL, June CH, Lane HC, Hodes RJ. **Telomere length, telomerase activity, and replicative potential in HIV infection: analysis of CD4+ and CD8+ T cells from HIV-discordant monozygotic twins.** *J Exp Med* 1997; **185**:1381–1386.
35. Pommier JP, Gauthier L, Livartowski J, Galanaud P, Boue F, Dulioust A, et al. **Immunosenescence in HIV pathogenesis.** *Virology* 1997; **231**:148–154.
36. Belge KU, Dayyani F, Horelt A, Siedlar M, Frankenberger M, Frankenberger B, et al. **The proinflammatory CD14+CD16+DR++ monocytes are a major source of TNF.** *J Immunol* 2002; **168**:3536–3542.
37. Fingerle G, Pforte A, Passlick B, Blumenstein M, Strobel M, Ziegler-Heitbrock HW. **The novel subset of CD14+/CD16+ blood monocytes is expanded in sepsis patients.** *Blood* 1993; **82**:3170–3176.
38. Nockher WA, Scherberich JE. **Expanded CD14+ CD16+ monocyte subpopulation in patients with acute and chronic infections undergoing hemodialysis.** *Infect Immun* 1998; **66**:2782–2790.
39. Heron M, Grutters JC, van Velzen-Blad H, Veltkamp M, Claessen AM, van den Bosch JM. **Increased expression of CD16, CD69, and very late antigen-1 on blood monocytes in active sarcoidosis.** *Chest* 2008; **134**:1001–1008.
40. Nyugen J, Agrawal S, Gollapudi S, Gupta S. **Impaired functions of peripheral blood monocyte subpopulations in aged humans.** *J Clin Immunol* 2010; **30**:806–813.
41. Thieblemont N, Weiss L, Sadeghi HM, Estcourt C, Haeflner-Cavaillon N. **CD14lowCD16high: a cytokine-producing monocyte subset which expands during human immunodeficiency virus infection.** *Eur J Immunol* 1995; **25**:3418–3424.
42. Jaworowski A, Ellery P, Maslin CL, Naim E, Heinlein AC, Ryan CE, et al. **Normal CD16 expression and phagocytosis of *Mycobacterium avium* complex by monocytes from a current cohort of HIV-1-infected patients.** *J Infect Dis* 2006; **193**:693–697.
43. Weiner LM, Li W, Holmes M, Catalano RB, Dohnarsky M, Padavic K, et al. **Phase I trial of recombinant macrophage colony-stimulating factor and recombinant gamma-interferon: toxicity, monocytosis, and clinical effects.** *Cancer Res* 1994; **54**:4084–4090.
44. Sotiriou SN, Orlova VV, Al-Fakhri N, Ihanus E, Economopoulou M, Isermann B, et al. **Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin.** *FASEB J* 2006; **20**:559–561.
45. van Royen N, Hoefler I, Bottinger M, Hua J, Grundmann S, Voskuil M, et al. **Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression.** *Circ Res* 2003; **92**:218–225.
46. Griffin JD, Spertini O, Ernst TJ, Belvin MP, Levine HB, Kanakura Y, et al. **Granulocyte-macrophage colony-stimulating factor and other cytokines regulate surface expression of the leukocyte adhesion molecule-1 on human neutrophils, monocytes, and their precursors.** *J Immunol* 1990; **145**:576–584.
47. Trial J, Birdsall HH, Hallum JA, Crane ML, Rodriguez-Barradas MC, de Jong AL, et al. **Phenotypic and functional changes in peripheral blood monocytes during progression of human immunodeficiency virus infection. Effects of soluble immune complexes, cytokines, subcellular particulates from apoptotic cells, and HIV-1-encoded proteins on monocytes phagocytic function, oxidative burst, transendothelial migration, and cell surface phenotype.** *J Clin Invest* 1995; **95**:1690–1701.
48. Rossen RD, Smith CW, Laughter AH, Noonan CA, Anderson DC, McShan WM, et al. **HIV-1-stimulated expression of CD11/CD18 integrins and ICAM-1: a possible mechanism for extravascular dissemination of HIV-1-infected cells.** *Trans Assoc Am Physicians* 1989; **102**:117–130.
49. Li W, Stanley ER. **Role of dimerization and modification of the CSF-1 receptor in its activation and internalization during the CSF-1 response.** *EMBO J* 1991; **10**:277–288.
50. Chen BD, Chou TH, Sensenbrenner L. **Downregulation of M-CSF receptors by lipopolysaccharide in murine peritoneal exudate macrophages is mediated through a phospholipase C dependent pathway.** *Exp Hematol* 1993; **21**:623–628.
51. Benoit M, Desnues B, Mege JL. **Macrophage polarization in bacterial infections.** *J Immunol* 2008; **181**:3733–3739.
52. Lambin P, Desjobert H, Debbia M, Fine JM, Muller JY. **Serum neopterin and beta 2-microglobulin in anti-HIV positive blood donors.** *Lancet* 1986; **2**:1216.
53. Stylianou E, Aukrust P, Bendtzen K, Muller F, Froland SS. **Interferons and interferon (IFN)-inducible protein 10 during highly active antiretroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection.** *Clin Exp Immunol* 2000; **119**:479–485.
54. Leng SX, Tian X, Matteini A, Li H, Hughes J, Jain A, et al. **IL-6-independent association of elevated serum neopterin levels with prevalent frailty in community-dwelling older adults.** *Age Ageing* 2011; **40**:475–481.
55. Murr C, Widner B, Wirleitner B, Fuchs D. **Neopterin as a marker for immune system activation.** *Curr Drug Metab* 2002; **3**:175–187.

56. Heller EA, Liu E, Tager AM, Yuan Q, Lin AY, Ahluwalia N, *et al.* **Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells.** *Circulation* 2006; **113**:2301–2312.
57. Fuchs D, Moller AA, Reibnegger G, Stockle E, Werner ER, Wachter H. **Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms.** *J Acquir Immune Defic Syndr* 1990; **3**:873–876.
58. Cinque P, Bestetti A, Marenzi R, Sala S, Gisslen M, Hagberg L, *et al.* **Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection.** *J Neuroimmunol* 2005; **168**:154–163.
59. Kolb SA, Sporer B, Lahrtz F, Koedel U, Pfister HW, Fontana A. **Identification of a T cell chemotactic factor in the cerebrospinal fluid of HIV-1-infected individuals as interferon-gamma inducible protein 10.** *J Neuroimmunol* 1999; **93**:172–181.
60. Luster AD, Unkeless JC, Ravetch JV. **Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins.** *Nature* 1985; **315**:672–676.
61. Burdo TH, Soulas C, Orzechowski K, Button J, Krishnan A, Sugimoto C, *et al.* **Increased monocyte turnover from bone marrow correlates with severity of SIV encephalitis and CD163 levels in plasma.** *PLoS Pathog* 2010; **6**:e1000842.
62. Vignoli M, Stecca B, Furlini G, Re MC, Mantovani V, Zauli G, *et al.* **Impaired telomerase activity in uninfected haematopoietic progenitors in HIV-1-infected patients.** *AIDS* 1998; **12**:999–1005.
63. Calado RT, Young NS. **Telomere diseases.** *N Engl J Med* 2009; **361**:2353–2365.
64. Kedzierska K, Mak J, Mijch A, Cooke I, Rainbird M, Roberts S, *et al.* **Granulocyte-macrophage colony-stimulating factor augments phagocytosis of *Mycobacterium avium* complex by human immunodeficiency virus type 1-infected monocytes/macrophages in vitro and in vivo.** *J Infect Dis* 2000; **181**:390–394.
65. Crowe SM, Vardaxis NJ, Kent SJ, Maerz AL, Hewish MJ, McGrath MS, *et al.* **HIV infection of monocyte-derived macrophages in vitro reduces phagocytosis of *Candida albicans*.** *J Leukoc Biol* 1994; **56**:318–327.